[go: up one dir, main page]

MX2015016963A - Metodos y composiciones para reducir la inmunosupresion por celulas de tumor. - Google Patents

Metodos y composiciones para reducir la inmunosupresion por celulas de tumor.

Info

Publication number
MX2015016963A
MX2015016963A MX2015016963A MX2015016963A MX2015016963A MX 2015016963 A MX2015016963 A MX 2015016963A MX 2015016963 A MX2015016963 A MX 2015016963A MX 2015016963 A MX2015016963 A MX 2015016963A MX 2015016963 A MX2015016963 A MX 2015016963A
Authority
MX
Mexico
Prior art keywords
methods
compositions
immunosupression
reducing
tumor cells
Prior art date
Application number
MX2015016963A
Other languages
English (en)
Inventor
Dranoff Glenn
W Wucherpfennig Kai
Zhou Penghui
SHAFFER Donald
Hacohen Nir
I Cantor Harvey
Alvarez Arias Diana
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of MX2015016963A publication Critical patent/MX2015016963A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

La presente invención provee, en parte, métodos de descubrimiento de objetivos de inmunoterapia in vivo, composiciones terapéuticas (p. ej., ARNhp, células inmunorrespondedoras que expresan ARNhp y/o receptores de antígeno quiméricos (CAR)), y métodos de uso de los mismos.
MX2015016963A 2013-06-10 2014-06-10 Metodos y composiciones para reducir la inmunosupresion por celulas de tumor. MX2015016963A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361833298P 2013-06-10 2013-06-10
US201361921303P 2013-12-27 2013-12-27
US201461929821P 2014-01-21 2014-01-21
PCT/US2014/041739 WO2014201021A2 (en) 2013-06-10 2014-06-10 Methods and compositions for reducing immunosupression by tumor cells

Publications (1)

Publication Number Publication Date
MX2015016963A true MX2015016963A (es) 2016-08-08

Family

ID=51063858

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015016963A MX2015016963A (es) 2013-06-10 2014-06-10 Metodos y composiciones para reducir la inmunosupresion por celulas de tumor.
MX2020001450A MX2020001450A (es) 2013-06-10 2015-12-09 Composiciones para reducir la inmunosupresion por celulas de tumor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001450A MX2020001450A (es) 2013-06-10 2015-12-09 Composiciones para reducir la inmunosupresion por celulas de tumor.

Country Status (11)

Country Link
US (4) US9944931B2 (es)
EP (2) EP3892293A1 (es)
JP (3) JP6546160B2 (es)
KR (3) KR20210115051A (es)
CN (1) CN105431524B (es)
AU (2) AU2014278323B2 (es)
CA (2) CA3051222C (es)
EA (1) EA035475B1 (es)
ES (1) ES2897579T3 (es)
MX (2) MX2015016963A (es)
WO (1) WO2014201021A2 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
US9944931B2 (en) * 2013-06-10 2018-04-17 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
US20170224731A1 (en) * 2014-06-10 2017-08-10 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
JP2018504145A (ja) * 2015-01-26 2018-02-15 セレクティスＣｅｌｌｅｃｔｉｓ 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL287500B2 (en) 2015-04-21 2023-12-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
US20200390811A1 (en) * 2015-04-23 2020-12-17 The Trustees Of The University Of Pennsylvania Compositions to disrupt protein kinase a anchoring and uses thereof
ES2886483T3 (es) * 2015-05-22 2021-12-20 Stcube & Co Inc Métodos de rastreo para dianas para la terapia contra el cáncer
KR20170054262A (ko) 2015-11-09 2017-05-17 사회복지법인 삼성생명공익재단 Socs가 억제된 면역억제능이 향상된 줄기세포 및 그의 이용
WO2017082562A1 (ko) * 2015-11-09 2017-05-18 사회복지법인 삼성생명공익재단 Socs가 억제된 면역억제능이 향상된 줄기세포 및 그의 이용
CN106967681B (zh) * 2016-01-13 2020-06-05 北京马力喏生物科技有限公司 治疗脑胶质母细胞瘤的治疗组合物
CN106967685B (zh) * 2016-01-13 2020-06-02 北京马力喏生物科技有限公司 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
CN107034193B (zh) * 2016-02-03 2020-06-05 北京马力喏生物科技有限公司 治疗b细胞白血病及b细胞淋巴瘤的治疗组合物
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
KR20230041739A (ko) * 2016-03-08 2023-03-24 매버릭 테라퓨틱스, 인크. 유도성 결합 단백질 및 사용 방법
CN110023330B (zh) 2016-04-08 2023-12-12 艾达普特免疫有限公司 T细胞受体
AU2017248121B2 (en) 2016-04-08 2022-07-21 Adaptimmune Limited T cell receptors
KR102529012B1 (ko) 2016-04-22 2023-05-09 크라제 메디컬 씨오 리미티드 세포성 면역요법을 위한 조성물 및 방법
CN110267677A (zh) * 2016-08-01 2019-09-20 诺华股份有限公司 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
CA3033736C (en) * 2016-08-12 2023-10-24 Toolgen Incorporated Manipulated immunoregulatory element and immunity altered thereby
KR102519166B1 (ko) * 2016-10-07 2023-04-07 세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지 Cd39의 발현을 억제하는 면역억제-복구 올리고뉴클레오타이드
CN107936109B (zh) * 2016-10-12 2022-02-08 香雪生命科学技术（广东）有限公司 衍生自sage1的肿瘤抗原短肽
CN107987156B (zh) * 2016-10-27 2022-10-21 中国科学院广州生物医药与健康研究院 识别sage1抗原短肽的tcr
CN107987155A (zh) * 2016-10-27 2018-05-04 中国科学院广州生物医药与健康研究院 识别sage1抗原短肽的t细胞受体
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
ES2916092T3 (es) 2016-12-08 2022-06-28 Immatics Biotechnologies Gmbh Nuevos receptores de linfocitos T e inmunoterapias basadas en el uso de los mismos
JP2020503043A (ja) * 2016-12-30 2020-01-30 セルラリティ インコーポレイテッド 遺伝子改変されたナチュラルキラー細胞
KR101793474B1 (ko) * 2017-01-04 2017-11-07 한국과학기술원 이노시톨 다인산 멀티키나아제 억제제를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
CN108342363B (zh) * 2017-01-25 2021-02-12 北京马力喏生物科技有限公司 共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
EP3585398A4 (en) * 2017-02-23 2020-08-19 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
CN110494557A (zh) 2017-03-27 2019-11-22 新加坡国立大学 用于离体扩增和活化自然杀伤细胞的刺激细胞系
KR20240057444A (ko) 2017-03-27 2024-05-02 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
CN107058232B (zh) * 2017-04-12 2018-03-30 上海优卡迪生物医药科技有限公司 胆固醇转脂酶soat1被抑制的car‑t细胞及其制备方法和应用
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
US12275963B2 (en) * 2017-05-08 2025-04-15 Toolgen Incorporated Artificially manipulated immune cell
CN108853144A (zh) * 2017-05-16 2018-11-23 科济生物医药（上海）有限公司 Toll样受体激动剂与免疫效应细胞的联用
KR101970764B1 (ko) 2017-05-19 2019-04-22 아주대학교산학협력단 조혈모세포의 항상성 유지에 관여하는 cotl1 단백질 및 이의 용도
CN109251980A (zh) * 2017-07-14 2019-01-22 中国人民解放军第八医院 膀胱癌组织t细胞图谱模型及其构建方法和构建系统
SG11202002089RA (en) 2017-09-08 2020-04-29 Maverick Therapeutics Inc Constrained conditionally activated binding proteins
SG11202006541UA (en) * 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
PT3737765T (pt) * 2018-01-12 2022-03-11 Curocell Inc Células imunitárias melhoradas utilizando shrna duplo e composição incluindo as mesmas
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
CN108424932B (zh) * 2018-03-13 2021-01-05 北京多赢时代转化医学研究院 重组溶瘤腺病毒、用于制备该重组溶瘤腺病毒的重组溶瘤腺病毒载体及其构建方法和应用
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019178420A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20210236548A1 (en) * 2018-04-20 2021-08-05 The Regents Of The University Of California Treatment of prostate cancer using chimeric antigen receptors
US20210317406A1 (en) 2018-07-09 2021-10-14 The Regents Of The University Of California Gene targets for t-cell-based immunotherapy
CR20210091A (es) * 2018-07-18 2021-03-24 Amgen Inc Receptores químericos de steap1 y métodos de uso de los mismos antecedentes de la invención
US20210325369A1 (en) * 2018-07-27 2021-10-21 Human Vaccines Project Predictive biomarkers for an immune response
AU2019327490A1 (en) * 2018-08-30 2021-03-25 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
JP2022519595A (ja) * 2019-02-04 2022-03-24 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子標的の組み合わせ
AU2020219069A1 (en) * 2019-02-08 2021-09-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Sirt2-ablated chimeric t cells
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
MX2021010670A (es) 2019-03-05 2021-11-12 Nkarta Inc Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
CN110101863A (zh) * 2019-04-04 2019-08-09 上海大学 抑制hipk1基因表达的应用
CN114127114B (zh) * 2019-04-30 2025-02-25 Absci公司 癌相关抗体组合物和使用方法
KR20220017922A (ko) * 2019-05-07 2022-02-14 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법에서의 otub1 표적화
EP4004218A4 (en) * 2019-07-30 2024-02-07 University Health Network T cell receptors and methods of use thereof
CN114555815A (zh) * 2019-07-30 2022-05-27 大学健康网络 T细胞受体及其使用方法
US20230107770A1 (en) * 2020-02-20 2023-04-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of enhancing immunotherapy using er stress pathway inhibitors
CN115968300A (zh) * 2020-05-11 2023-04-14 艾宾妥斯生物公司 用于体内转导的载体和方法
CN113827727B (zh) * 2020-06-24 2025-04-29 上海交通大学医学院附属瑞金医院 Ptpn2抑制剂在kras突变肿瘤中的应用
CA3188143A1 (en) * 2020-06-25 2021-12-30 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
IL301045A (en) * 2020-09-01 2023-05-01 Nat Inst Biotechnology Negev Ltd Immune system restoration by cell therapy
CN112080527A (zh) * 2020-09-16 2020-12-15 南京市第一医院 重组表达载体、耗竭减少的嵌合抗原受体t细胞及其应用
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
JP7681279B2 (ja) 2021-03-12 2025-05-22 富士フイルム株式会社 関節症治療剤の製造方法及び関節症治療剤
WO2022204487A1 (en) * 2021-03-26 2022-09-29 Duke University Systems and methods for exosome delivery of micrornas for cellular reprogramming
EP4299710A4 (en) * 2021-03-31 2024-08-28 PHC Corporation INFORMATION MANAGEMENT DEVICE AND COMPUTER PROGRAM
US20240191226A1 (en) * 2021-04-23 2024-06-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Smad2 inhibition in beta cells for type 2 diabetes therapy
CN113736742B (zh) * 2021-09-08 2023-07-21 河南省医药科学研究院 Prtn3基因作为肿瘤免疫治疗中激活细胞毒性免疫细胞靶点的应用
PE20241173A1 (es) 2021-10-14 2024-05-28 Arsenal Biosciences Inc Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
WO2023137437A2 (en) * 2022-01-14 2023-07-20 Regents Of The University Of Minnesota Materials and methods for incorporating a transgene into the socs3 locus of an immune cell
CN118256444A (zh) * 2022-04-26 2024-06-28 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
CN116004623B (zh) * 2022-10-19 2023-09-01 威海市立医院 一种靶向沉默LRP1基因表达的shRNA序列、其制备方法和应用
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
JP2003533991A (ja) 2000-05-23 2003-11-18 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・（イ・エヌ・エス・ウ・エール・エム） 新生児インスリン依存性糖尿病及び多発性骨端異形成症（ウオルコット−ラリソン症候群）の患者における変異した真核生物の翻訳開始因子２アルファキナーゼ３，ｅｉｆ２ａｋ３
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
WO2008033403A2 (en) * 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Agents and methods to elicit anti-tumor immune response
WO2009062199A1 (en) 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
AT506041A1 (de) 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
CN201789682U (zh) 2010-07-23 2011-04-06 中兴通讯股份有限公司 四层通孔印刷电路板及应用该印刷电路板的移动终端
WO2012038918A1 (en) * 2010-09-23 2012-03-29 Centre National De La Recherche Scientifique (Cnrs) Therapeutic product inhibitor of the cell proliferation and biological applications thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013121042A1 (en) * 2012-02-16 2013-08-22 Vib Vzw PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
CN103113470B (zh) * 2013-02-27 2015-04-22 四川大学 靶向人egfr的基因工程化淋巴细胞及其制备方法和用途
US9944931B2 (en) * 2013-06-10 2018-04-17 Dana-Farber Cancer Institute, Inc. Methods and compositions for reducing immunosupression by tumor cells

Also Published As

Publication number Publication date
JP2016526883A (ja) 2016-09-08
EA035475B1 (ru) 2020-06-23
AU2020223762A1 (en) 2020-09-17
AU2014278323A1 (en) 2015-11-26
JP6546160B2 (ja) 2019-07-17
MX2020001450A (es) 2020-03-24
JP7219254B2 (ja) 2023-02-07
KR20160018525A (ko) 2016-02-17
US20180327750A1 (en) 2018-11-15
JP2019176868A (ja) 2019-10-17
KR102301464B1 (ko) 2021-09-14
US20210139914A1 (en) 2021-05-13
US20230383298A1 (en) 2023-11-30
CA2912389A1 (en) 2014-12-18
KR20210115051A (ko) 2021-09-24
WO2014201021A2 (en) 2014-12-18
BR112015030822A2 (pt) 2017-12-12
EP3008173A2 (en) 2016-04-20
KR20230005422A (ko) 2023-01-09
CN105431524B (zh) 2020-04-21
WO2014201021A3 (en) 2015-02-26
US9944931B2 (en) 2018-04-17
EP3892293A1 (en) 2021-10-13
CN105431524A (zh) 2016-03-23
CA2912389C (en) 2020-01-28
AU2014278323B2 (en) 2020-05-28
ES2897579T3 (es) 2022-03-01
EA201592269A1 (ru) 2016-05-31
CA3051222A1 (en) 2014-12-18
US11597934B2 (en) 2023-03-07
EP3008173B1 (en) 2021-09-15
US20160122766A1 (en) 2016-05-05
JP2021040648A (ja) 2021-03-18
US10876120B2 (en) 2020-12-29
CA3051222C (en) 2023-01-24

Similar Documents

Publication Publication Date Title
MX2015016963A (es) Metodos y composiciones para reducir la inmunosupresion por celulas de tumor.
AR120262A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CR20190199A (es) Anticuerpos anti-pd-1 y sus usos
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
UY36968A (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
MX2020001752A (es) Anticuerpos anti-cd3 y metodos de uso.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
CA2924268C (en) Anti-alpha-synuclein antibodies and methods of use
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
MX2015011095A (es) Composiciones y metodos para inmunoterapia.
MX2017006770A (es) Conjugados de pirrolobenzodiazepina y anticuerpo.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
MX2016009877A (es) Anticuerpos anti-baff novedosos.
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
MX2014006187A (es) Composiciones y metodos para el analisis de cancer de prostata.
CL2019003557A1 (es) Anticuerpos anti-trkb.
MX353951B (es) Anticuerpos de anti-teofilina y metodos de uso.
AR117596A2 (es) Anticuerpos anti-cd3 y métodos de uso
AR113854A1 (es) Anticuerpos anti-cxcr5, composiciones y usos de los mismos
AR103294A1 (es) Composiciones y procedimientos para la glicosilación de proteínas

Legal Events

Date Code Title Description
FG Grant or registration